Literature DB >> 19962619

The Disease Activity Score and the EULAR response criteria.

Jaap Fransen1, Piet L C M van Riel.   

Abstract

The Disease Activity Score (DAS), its modified version the DAS28, and the DAS-based European League Against Rheumatism (EULAR) response criteria are well-known measures of disease activity in rheumatoid arthritis (RA). The DAS is a clinical index of RA disease activity that combines information from swollen joints, tender joints, the acute phase response, and general health. The EULAR response criteria classify individual patients as non-, moderate, or good responders, depending on the extent of change and the level of disease activity reached. The DAS, DAS28, and EULAR response criteria have been validated extensively. For daily practice, it has been shown that a tight control strategy, including measurement of disease activity using the DAS and planned adjustment of antirheumatic medication, is an effective strategy for RA. This article summarizes the development and validation of the DAS and DAS28 and their use in clinical trials and practice for the clinician.

Entities:  

Mesh:

Year:  2009        PMID: 19962619     DOI: 10.1016/j.rdc.2009.10.001

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  97 in total

1.  Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice?

Authors:  Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2011-09-29       Impact factor: 2.980

Review 2.  Biomarkers to guide clinical therapeutics in rheumatology?

Authors:  William H Robinson; Rong Mao
Journal:  Curr Opin Rheumatol       Date:  2016-03       Impact factor: 5.006

3.  Enhanced COMP catabolism detected in serum of patients with arthritis and animal disease models through a novel capture ELISA.

Authors:  Y Lai; X-P Yu; Y Zhang; Q Tian; H Song; M T Mucignat; R Perris; J Samuels; S Krasnokutsky; M Attur; J D Greenberg; S B Abramson; P E Di Cesare; C J Liu
Journal:  Osteoarthritis Cartilage       Date:  2012-05-14       Impact factor: 6.576

4.  Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis.

Authors:  Lucia Lauková; Barbora Konečná; Barbora Vlková; Vanda Mlynáriková; Peter Celec; Emőke Šteňová
Journal:  Rheumatol Int       Date:  2018-05-23       Impact factor: 2.631

5.  Association between helplessness, disability, and disease activity with health-related quality of life among rheumatoid arthritis patients in a multiethnic Asian population.

Authors:  Yu Heng Kwan; Ee Tzun Koh; Khai Pang Leong; Hwee-Lin Wee
Journal:  Rheumatol Int       Date:  2014-01-09       Impact factor: 2.631

6.  Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.

Authors:  Yoshikazu Ogawa; Nobunori Takahashi; Atsushi Kaneko; Yuji Hirano; Yasuhide Kanayama; Yuichiro Yabe; Takeshi Oguchi; Takayoshi Fujibayashi; Hideki Takagi; Masahiro Hanabayashi; Koji Funahashi; Masatoshi Hayashi; Seiji Tsuboi; Shuji Asai; Nobuyuki Asai; Takuya Matsumoto; Yasumori Sobue; Naoki Ishiguro; Toshihisa Kojima
Journal:  Clin Rheumatol       Date:  2019-06-10       Impact factor: 2.980

7.  Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics.

Authors:  J L Barton; L Trupin; D Schillinger; S A Gansky; C Tonner; M Margaretten; V Chernitskiy; J Graf; J Imboden; E Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

8.  Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.

Authors:  Bruce Kirkham; Khaldoun Chaabo; Christopher Hall; Toby Garrood; Timothy Mant; Elizabeth Allen; Alexandra Vincent; Joana C Vasconcelos; Andrew T Prevost; Gabriel S Panayi; Valerie M Corrigall
Journal:  Rheumatology (Oxford)       Date:  2016-08-07       Impact factor: 7.580

9.  A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.

Authors:  Claudia Kedor; Jan Zernicke; Anja Hagemann; Lorena Martinez Gamboa; Johanna Callhoff; Gerd-Rüdiger Burmester; Eugen Feist
Journal:  Clin Rheumatol       Date:  2016-07-28       Impact factor: 2.980

10.  Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

Authors:  Florenzo Iannone; Delphine S Courvoisier; Jacques Eric Gottenberg; Maria Victoria Hernandez; Elisabeth Lie; Helena Canhão; Karel Pavelka; Merete Lund Hetland; Carl Turesson; Xavier Mariette; Denis Choquette; Axel Finckh
Journal:  Clin Rheumatol       Date:  2016-12-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.